<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245765</url>
  </required_header>
  <id_info>
    <org_study_id>C87040</org_study_id>
    <secondary_id>2005-002141-39</secondary_id>
    <nct_id>NCT00245765</nct_id>
  </id_info>
  <brief_title>Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy</brief_title>
  <official_title>Multicenter, Dose Response, Randomized, Double Blind, Parallel, Placebo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of Subcutaneous CDP870 in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo,
      administered during 12 weeks, to patients suffering from moderate to severe chronic plaque
      psoriasis, extended by a 12 to 24 week follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI75 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 75 %.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achievement of a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The overall severity of the disease was evaluated using the following 6-point scale:
5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema
1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Psoriasis Activity and Severity Index 50 (PASI50)</measure>
    <time_frame>During the 12-weeks Treatment Period</time_frame>
    <description>Time to PASI50 is defined as the time elapsed between the start of the Treatment Period (Week 0) and the first occurrence of PASI50 during the Treatment Period.
This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Psoriasis Activity and Severity Index 75 (PASI75)</measure>
    <time_frame>During the 12-weeks Treatment Period</time_frame>
    <description>Time to PASI75 is defined as the time elapsed between the start of the Treatment Period (Week 0) and the first occurrence of PASI75 during the Treatment Period.
This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Relapse</measure>
    <time_frame>During the 12-weeks Treatment Period</time_frame>
    <description>Time to relapse is defined as the time elapsed between the last dose and when maximal improvement in PASI from Baseline was reduced by &gt; 50 %. This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of a Psoriasis Activity and Severity Index (PASI50) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI50 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 50 %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of a Psoriasis Activity and Severity Index (PASI90) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI90 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 90 %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Experience of a Rebound Effect Within 2 Months After Stopping Therapy</measure>
    <time_frame>Within 2 months of stopping therapy</time_frame>
    <description>Rebound is defined as worsening of psoriasis over baseline value with more than 125 % or new pustular, erythrodermic or more inflammatory psoriasis within 2 months of stopping therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Body Surface Area (BSA) Affected by Psoriasis at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Two methods were used for the evaluation of BSA:
The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Week 12</measure>
    <time_frame>Baseline up to Week 12</time_frame>
    <description>Two methods were used for the evaluation of BSA:
The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation From the Treatment Period Due to Lack of Efficacy or Worsening of Psoriasis</measure>
    <time_frame>During the 12-week Treatment Period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injections of Placebo every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Certolizumab Pegol 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Certolizumab Pegol 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injections of 400 mg every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab Pegol</intervention_name>
    <description>Pharmaceutical Form: solution for injection in pre-filled syringe
Route of Administration: subcutaneous use</description>
    <arm_group_label>Certolizumab Pegol 200 mg</arm_group_label>
    <arm_group_label>Certolizumab Pegol 400 mg</arm_group_label>
    <other_name>Cimzia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo to Certolizumab Pegol</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women &gt; 18 years

          -  Subjects with chronic plaque psoriasis stable for at least 3 months and moderate to
             severe for at least 6 months

          -  Subjects with Psoriasis Area and Severity Index (PASI) ≥ 12 and Body Surface Area
             (BSA) ≥ 10 %

          -  Subjects were candidates for systemic psoriasis therapy and/or phototherapy and/or
             photochemotherapy

        Exclusion Criteria:

          -  Subjects with an erythrodermic, guttate, palmar or plantar, generalized pustular form
             of psoriasis

          -  A history of chronic infection, recent serious or life-threatening infection (within
             six months, including herpes zoster), or any current sign or symptom that may indicate
             an infection (e.g. fever, cough);

          -  White blood cell counts less than 4000/mm^3 or more than 20000/mm^3

          -  Suspected or diagnosed demyelinating disease of the central nervous system (e.g.
             multiple sclerosis or optic neuritis)

          -  Systemic Lupus

          -  Non respect of adequate wash out periods for treatments that might have an impact on
             the disease

          -  Any associated disease that could be impacted by the study treatment intake

          -  Any other condition, which in the Investigator's judgment would make the subject
             unsuitable for inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice Cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/C87040_CSS_20080529.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <results_reference>
    <citation>Ortonne JP, Tasset C, Reich K. Efficacy of certolizumab pegol, a PEGylated Fab' fragment of an anti-alpha monoclonal antibody, in patients previously exposed to biologicals: preliminary results of a randomised, placebo-controlled, phase II clinical trial in psoriasis. J.Eur.Acad.Dermatol.Venereol. 22[Suppl 1], 2007. Vienna, 16th Congress of the European Academy of Dermatology and Venereology (EADV), May 16-20, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Sterry W, Tasset C, Reich K. Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNF-alpha monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: preliminary results from a double-blind, placebo-controlled trial. J.Am.Acad.Dermatol. 56[Suppl 2], AB6. 2007. Washington, DC, 65th Annual Meeting of the American Academy of Dermatology (AAAD), February 2-7, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Reich K, Tasset C, Ortonne J. Efficacy and safety of certolizumab pegol, in patients with chronic plaque psoriasis: preliminary results of a randomized, double-blind, placebo-controlled trial. Ann.Rheum.Dis. 66[Suppl 2], 251. 2007. Barcelona, Annual European Congress of Rheumatology EULAR 2007, June 13-16, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Sterry W, Tasset C, Reich K. Certolizumab pegol, the first pegylated anti-TNF alpha, is effective and well tolerated in patients with moderate-to-severe chronic plaque psoriasis: preliminary data from a phase II study. J.Eur.Acad.Dermatol.Venereol. 21[Suppl 1], 26. 2007. Rhodes, Greece, 15th Congress of the European Academy of Dermatology and Venereology (EADV), October 4-8, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Sterry W, Coteur G, Keininger DL, Reich K. Improved health-related quality of life in psoriasis patients following 10 weeks' treatment with certolizumab pegol: data from a Phase II study. 2007. Buenos Aires, Argentina, 21st World Congress of Dermatology, October 1-5, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Reich K, Sterry W, Tasset C, Terpstra I, Ortonne JP. Efficacy and time to relapse with certolizumab pegol, the first pegylated anti-TNF alpha agent, in patients with moderate-to-severe chronic plaque psoriasis: Phase II study results. 2007. Buenos Aires, Argentina, 21st World Congress of Dermatology, October 1-5, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Reich K, Sterry W, Terpstra I. Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial. J.Am.Acad.Dermatol. 58[Suppl 2], AB4. 2008. San Antonio, 66th Annual Meeting of the American Academy of Dermatology (AAD), February 1-5, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Reich K, Keininger DL. Certolizumab pegol improved health-related quality of life in patients with psoriasis: Data from a phase II study. J.Am.Acad.Dermatol. 58[Suppl 2], AB121. 2008. San Antonio, 66th Annual Meeting of the American Academy of Dermatology (AAD), February 1-5, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012 Jul;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x. Epub 2012 Jun 11.</citation>
    <PMID>22413944</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 26, 2005</study_first_submitted>
  <study_first_submitted_qc>October 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2005</study_first_posted>
  <results_first_submitted>June 22, 2018</results_first_submitted>
  <results_first_submitted_qc>January 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2019</results_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2019</last_update_posted>
  <keyword>chronic plaque psoriasis, anti TNFα</keyword>
  <keyword>CDP870, Cimzia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in October 2005 and concluded in November 2006.</recruitment_details>
      <pre_assignment_details>The study included a 12-week Treatment Period and a 12 to 24-week Follow-up Period. Participant Flow refers to the Intention-to-treat Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (ITT)</title>
          <description>Subcutaneous injections of Placebo every 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Certolizumab Pegol 200 mg (ITT)</title>
          <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
        </group>
        <group group_id="P3">
          <title>Certolizumab Pegol 400 mg (ITT)</title>
          <description>Subcutaneous injections of 400 mg every 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="58">One subject in the Placebo (PBO) group received one injection of CDP870 200 mg on one occasion.</participants>
                <participants group_id="P2" count="60">For safety analysis, the PBO group subj. who received CDP870 was considered to be in the 200mg group</participants>
                <participants group_id="P3" count="57">One subject in the 400 mg group was randomized by mistake but did not receive study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (ITT)</title>
          <description>Subcutaneous injections of Placebo every 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Certolizumab Pegol 200 mg (ITT)</title>
          <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
        </group>
        <group group_id="B3">
          <title>Certolizumab Pegol 400 mg (ITT)</title>
          <description>Subcutaneous injections of 400 mg every 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.30" spread="12.78"/>
                    <measurement group_id="B2" value="43.26" spread="10.12"/>
                    <measurement group_id="B3" value="43.64" spread="12.36"/>
                    <measurement group_id="B4" value="43.40" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12</title>
        <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI75 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 75 %.</description>
        <time_frame>Week 12</time_frame>
        <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12</title>
          <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI75 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 75 %.</description>
          <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="74.6"/>
                    <measurement group_id="O3" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression with treatment and baseline severity of psoriasis as factors.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>40.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.7</ci_lower_limit>
            <ci_upper_limit>150.3</ci_upper_limit>
            <estimate_desc>Confidence limits are based on likelihood ratio statistics.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression with treatment and baseline severity of psoriasis as factors.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>73.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23.5</ci_lower_limit>
            <ci_upper_limit>292.6</ci_upper_limit>
            <estimate_desc>Confidence limits are based on likelihood ratio statistics.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Achievement of a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12</title>
        <description>The overall severity of the disease was evaluated using the following 6-point scale:
5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema
1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)</description>
        <time_frame>Week 12</time_frame>
        <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12</title>
          <description>The overall severity of the disease was evaluated using the following 6-point scale:
5 = Severe: Very marked plaque elevation, scaling, and/or erythema. 4 = Moderate to severe: Marked plaque elevation, scaling, and/or erythema. 3 = Moderate: Moderate plaque elevation, scaling, and/or erythema. 2 = Mild: Slight plaque elevation, scaling, and/or erythema
1 = Almost clear: Intermediate between mild and clear 0 = Clear: No signs of psoriasis (post-inflammatory hyperpigmentation may be present)</description>
          <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="52.5"/>
                    <measurement group_id="O3" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression with treatment and baseline severity of psoriasis as factors. Confidence limits are based on likelihood ratio statistics.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>64.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.7</ci_lower_limit>
            <ci_upper_limit>1169.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression with treatment and baseline severity of psoriasis as factors.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>162.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>31.4</ci_lower_limit>
            <ci_upper_limit>2999.2</ci_upper_limit>
            <estimate_desc>Confidence limits are based on likelihood ratio statistics.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Psoriasis Activity and Severity Index 50 (PASI50)</title>
        <description>Time to PASI50 is defined as the time elapsed between the start of the Treatment Period (Week 0) and the first occurrence of PASI50 during the Treatment Period.
This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
        <time_frame>During the 12-weeks Treatment Period</time_frame>
        <population>Only those subjects from the Intention-To-Treat (ITT) population who are PASI75 responder at Week 12 are included in the analysis of this variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Psoriasis Activity and Severity Index 50 (PASI50)</title>
          <description>Time to PASI50 is defined as the time elapsed between the start of the Treatment Period (Week 0) and the first occurrence of PASI50 during the Treatment Period.
This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
          <population>Only those subjects from the Intention-To-Treat (ITT) population who are PASI75 responder at Week 12 are included in the analysis of this variable.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.50" lower_limit="14.00" upper_limit="99.00"/>
                    <measurement group_id="O2" value="21.00" lower_limit="20.00" upper_limit="28.00"/>
                    <measurement group_id="O3" value="22.00" lower_limit="21.00" upper_limit="30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Psoriasis Activity and Severity Index 75 (PASI75)</title>
        <description>Time to PASI75 is defined as the time elapsed between the start of the Treatment Period (Week 0) and the first occurrence of PASI75 during the Treatment Period.
This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
        <time_frame>During the 12-weeks Treatment Period</time_frame>
        <population>Only those subjects from the Intention-To-Treat (ITT) population who are PASI75 responder at Week 12 are included in the analysis of this variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Psoriasis Activity and Severity Index 75 (PASI75)</title>
          <description>Time to PASI75 is defined as the time elapsed between the start of the Treatment Period (Week 0) and the first occurrence of PASI75 during the Treatment Period.
This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
          <population>Only those subjects from the Intention-To-Treat (ITT) population who are PASI75 responder at Week 12 are included in the analysis of this variable.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.50" lower_limit="42.00" upper_limit="99.00"/>
                    <measurement group_id="O2" value="42.50" lower_limit="28.00" upper_limit="56.00"/>
                    <measurement group_id="O3" value="55.50" lower_limit="42.00" upper_limit="69.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Relapse</title>
        <description>Time to relapse is defined as the time elapsed between the last dose and when maximal improvement in PASI from Baseline was reduced by &gt; 50 %. This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
        <time_frame>During the 12-weeks Treatment Period</time_frame>
        <population>Only those subjects from the Intention-To-Treat (ITT) population who are PASI75 responder at Week 12 are included in the analysis of this variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Relapse</title>
          <description>Time to relapse is defined as the time elapsed between the last dose and when maximal improvement in PASI from Baseline was reduced by &gt; 50 %. This variable is defined only for those patients who have achieved PASI75 at the end of the Treatment Period (Week 12).</description>
          <population>Only those subjects from the Intention-To-Treat (ITT) population who are PASI75 responder at Week 12 are included in the analysis of this variable.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">This parameter applied only to those subjects who had achieved PASI75 at the end of the treatment period and who had an event of relapse.</measurement>
                    <measurement group_id="O2" value="22.14" lower_limit="17.00" upper_limit="26.00"/>
                    <measurement group_id="O3" value="20.14" lower_limit="17.00" upper_limit="22.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of a Psoriasis Activity and Severity Index (PASI50) Response at Week 12</title>
        <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI50 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 50 %.</description>
        <time_frame>Week 12</time_frame>
        <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of a Psoriasis Activity and Severity Index (PASI50) Response at Week 12</title>
          <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI50 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 50 %.</description>
          <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="86.4"/>
                    <measurement group_id="O3" value="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of a Psoriasis Activity and Severity Index (PASI90) Response at Week 12</title>
        <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI90 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 90 %.</description>
        <time_frame>Week 12</time_frame>
        <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Achievement of a Psoriasis Activity and Severity Index (PASI90) Response at Week 12</title>
          <description>Determining the PASI score involves the evaluation of erythema, infiltration, and desquamation and body surface area involvement over 4 body regions. These regions are the head, trunk, upper and lower extremities.
PASI90 response at Week 12 is defined as a decrease in PASI score at Week 12 from Baseline of at least 90 %.</description>
          <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="39.0"/>
                    <measurement group_id="O3" value="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Experience of a Rebound Effect Within 2 Months After Stopping Therapy</title>
        <description>Rebound is defined as worsening of psoriasis over baseline value with more than 125 % or new pustular, erythrodermic or more inflammatory psoriasis within 2 months of stopping therapy.</description>
        <time_frame>Within 2 months of stopping therapy</time_frame>
        <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Experience of a Rebound Effect Within 2 Months After Stopping Therapy</title>
          <description>Rebound is defined as worsening of psoriasis over baseline value with more than 125 % or new pustular, erythrodermic or more inflammatory psoriasis within 2 months of stopping therapy.</description>
          <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Body Surface Area (BSA) Affected by Psoriasis at Week 12</title>
        <description>Two methods were used for the evaluation of BSA:
The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)</description>
        <time_frame>Week 12</time_frame>
        <population>ITT population consisting of all randomized subjects. The analysis was performed for week 12 using observed case data (i.e., no imputation was performed for missing data). By week 12, there were 29 patients who had prematurely discontinued the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Body Surface Area (BSA) Affected by Psoriasis at Week 12</title>
          <description>Two methods were used for the evaluation of BSA:
The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %)</description>
          <population>ITT population consisting of all randomized subjects. The analysis was performed for week 12 using observed case data (i.e., no imputation was performed for missing data). By week 12, there were 29 patients who had prematurely discontinued the study.</population>
          <units>percentage of affected Body Surface Area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="17.2"/>
                    <measurement group_id="O2" value="7.1" spread="9.3"/>
                    <measurement group_id="O3" value="5.6" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Week 12</title>
        <description>Two methods were used for the evaluation of BSA:
The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.</description>
        <time_frame>Baseline up to Week 12</time_frame>
        <population>ITT population consisting of all randomized subjects. The analysis was performed for week 12 using observed case data (i.e., no imputation was performed for missing data). By week 12, there were 29 patients who had prematurely discontinued the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in the Body Surface Area (BSA) Affected by Psoriasis at Week 12</title>
          <description>Two methods were used for the evaluation of BSA:
The area of one side of a subject's flat closed hand was used to represent 1 % to the total body surface area (BSA) to estimate the extent of skin involvement in subjects with psoriasis
The rule of nines method assumed that the total BSA comprises head (9 %), anterior trunk (upper, 9 %; lower, 9 %), posterior trunk (upper, 9 %; lower, 9 %), each leg (anterior, 9 %; posterior, 9 %), each arm (9 %) and genitalia (1 %) A positive value in Change from Baseline indicates an improvement from Baseline. The higher the positive value, the higher the change.</description>
          <population>ITT population consisting of all randomized subjects. The analysis was performed for week 12 using observed case data (i.e., no imputation was performed for missing data). By week 12, there were 29 patients who had prematurely discontinued the study.</population>
          <units>Percent of total Body surface area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="11.9"/>
                    <measurement group_id="O2" value="18.3" spread="15.1"/>
                    <measurement group_id="O3" value="22.6" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation From the Treatment Period Due to Lack of Efficacy or Worsening of Psoriasis</title>
        <time_frame>During the 12-week Treatment Period</time_frame>
        <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (ITT)</title>
            <description>Subcutaneous injections of Placebo every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Certolizumab Pegol 200 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
          </group>
          <group group_id="O3">
            <title>Certolizumab Pegol 400 mg (ITT)</title>
            <description>Subcutaneous injections of 400 mg every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation From the Treatment Period Due to Lack of Efficacy or Worsening of Psoriasis</title>
          <population>Intention-To-Treat (ITT) population consisting of all randomized subjects.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" lower_limit="21.0" upper_limit="75.0"/>
                    <measurement group_id="O2" value="59.5" lower_limit="35.0" upper_limit="70.0"/>
                    <measurement group_id="O3" value="49.0" lower_limit="21.0" upper_limit="77.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from Baseline (Week 0) over the 12-weeks Treatment Period until the end of the Follow-up Period (up to 36 weeks).</time_frame>
      <desc>The safety population consisted of all subjects who were exposed to study medication. One subject in the PBO group received one injection of CDP870 200 mg on one occasion. In the safety analysis, this subject was considered to be in the 200 mg group. One subject in the 400 mg group was randomized by mistake but did not receive study medication. This subject discontinued from the study due to an adverse event. This subject was randomized and is part of the ITT population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (SS)</title>
          <description>Subcutaneous injections of Placebo every 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Certolizumab Pegol 200 mg (SS)</title>
          <description>Subcutaneous injections of 400 mg initial dose at week 0 with 200 mg every 2 weeks thereafter</description>
        </group>
        <group group_id="E3">
          <title>Certolizumab Pegol 400 mg (SS)</title>
          <description>Subcutaneous injections of 400 mg every 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection site irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

